Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Business Wire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 total revenues $658.7 million, up from $597.8 million year over year
- ➤Q3 GAAP diluted EPS $0.85; non-GAAP diluted EPS $0.94
- ➤2026 revenue guidance unchanged at $2.500 billion-$2.550 billion
- ➤2026 effective tax-rate guidance reduced to 16%-18% from 21%-23%
- ➤STELLAR-304 topline results expected in first quarter of 2027
- ➤$402.1 million repurchased under May 2026 stock repurchase program
Expert Statements
Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis
“Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity.”
Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis
“The zanzalintinib development program gained further momentum as the organization focused on trial initiations, enrollment progress for ongoing studies and in-depth planning for the next wave of new pivotal trials.”
Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis
“The enthusiasm around the zanzalintinib franchise continues, and we look forward to sharing more progress when appropriate.”
Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis
“As we execute on our priorities, we remain disciplined in our deployment of capital as we invest in our R&D portfolio, return value to shareholders through our stock repurchase program and actively evaluate external innovation opportunities that can strengthen our pipeline and create long-term value for patients and all of our stakeholders.”
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million –
Get started
Create a free account to read the full story.